Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Host Sage FutureCast Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 20, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that it will host Sage
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
Pipeline progress continues with first patient dosed and ongoing enrollment in multiple clinical trials across the depression and neurology franchises Durability of response was observed in patients with MDD who responded to a 2-week treatment with zuranolone in MOUNTAIN Study six-month follow-up
View HTML
Toggle Summary Sage Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics to Present at Goldman Sachs 41st Annual Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 1, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics to Present at Bank of America Health Care Conference 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at
View HTML
Toggle Summary Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
Expected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M , with significant portion related to
View HTML
Toggle Summary Sage Therapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 16, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics Announces Restructuring to Advance Corporate Strategy and Pipeline
Changes are expected to result in annualized cost savings of approximately $170 million , including SG&A savings of $150 million Headcount reduction of 340 – approximately 53 percent of workforce Current balance of cash, cash equivalents, restricted cash, and marketable securities expected to
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on April 1, 2020 , the
View HTML